HELUS PHARMA INC
HELPNASDAQTrading Snapshot
- Day Range
- $10.51 – $11.30
- 52-Week Range
- $3.76 – $15.15
- Volume (shares)
- 785,679
- Avg Volume (shares)
- —
- Shares Outstanding
- 62.0M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -2.6
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-3.35
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +116.1%
HELUS PHARMA INC
HELP
StockOtter · stockotter.spaceAbout HELUS PHARMA INC
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Helus Pharma Announces Co-Founders' Transition from Executive Leadership as Company Advances Toward Next Stage of Development
Co-founders to step down from executive roles and continue to serve on the Board of Directors Helus Pharma board member, Mark Lawson, appointed as new independent Chair of the Board of Directors, effective immediately Th
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder (“MDD”) on track for Q4 20261,2
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on De
Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout
Helus Pharma remains a buy, as HLP003's Phase 3 APPROACH topline data in 4Q26 is the key near-term catalyst. HLP003 targets adjunctive MDD with a differentiated intermittent dosing model; prior Phase 2 data showed a 23-p
Helus Pharma to Host Investor Presentation on October 21, 2026
NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing n
Helus Pharma Announces Completion of Legal Name Change
NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel